WASHINGTON AP – As Congress returns from summer recess, lawmakers are expected to continue needling pharmaceutical makers and health insurers with investigations, while holding off on major health care reform until next year.
Democrats this year have launched probes of some of the country’s largest drugmakers and passed laws curbing marketing tactics used by insurers. Analysts expect those efforts to continue this fall while party leaders begin laying the groundwork for broader changes after the November elections.
